Late-onset schizophrenia is relatively common. Onset after the age of 40 years is reported in 23% of patients hospitalised with schizophrenia. The condition is different from early-onset schizophrenia on a number of counts, including the response to antipsychotic drugs. This Cochrane review set out to assess the effects of antipsychotic drugs for elderly people with [read the full story…]
There has been concern about the rate of use of antipsychotic mecdication for people with learning disabilities for some time. We have posted a number of studies which have raised questions about efficacy and rate of use here on this blog. The authors of this study were concerned to look at prescription rates in people [read the full story…]
This new systematic review compares how effective first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) are at preventing relapse in patients with schizophrenia. The authors carried out a meta-analysis of 23 randomised controlled trials that lasted for ≥6 months and compared FGAs with SGAs in schizophrenia. The outcomes they studied were: Study defined relapse Relapse at 3, [read the full story…]
There’s an interesting review in the British Journal of Psychiatry this week, which compares the effectiveness of psychiatric drugs with those used to treat physical health problems. The headline from the review is that ‘psychiatric drugs are as effective as other drugs’. Professor Stefan Leucht who led the review team claims that: There is a [read the full story…]
This ‘optimal use’ project from the Canadian Agency for Drugs and Technologies in Health assesses the clinical and economic impact of using atypical antipsychotic combination therapy, as well as high-dosing treatment strategies, in adolescents and adults with schizophrenia. The report was produced by an expert panel who based their recommendations on a systematic review and [read the full story…]
Patients with first episode psychosis often relapse after initial remission, so it is perhaps surprising that treatment guidelines for the condition are generally based on poor quality evidence. Antipsychotic drugs are frequently discontinued, but clinicians don’t have ready access to information that shows how to determine which patients can be successfully tapered off of antipsychotic [read the full story…]
This systematic literature review and meta-analysis conducted by researchers from the University of Nebraska Medical Center, will be of interest to all clinicians who treat paediatric bipolar disorder. Treatment decisions for young people have previously been based on extrapolation from adult trials, case reports, open label trials or expert opinion. This new study provides a [read the full story…]
This systematic review set out to look at the efficacy of atypical antipsychotic medication, also known as second generation antipsychotics, commonly used in the treatment of schizophrenia. There continues to be debate around whether these second-generation medications are safer or more effective than typical antipsychotics as they still can produce severe side effects. Other posts [read the full story…]
People with generalised anxiety disorder (GAD) often fail to achieve remission (recovering fully from their disease) despite standard treatments. This systematic review examines the efficacy and tolerability of second-generation antipsychotics (SGAs) for generalised anxiety disorder as either: augmentation therapy, i.e. using it alongside other treatments monotherapy, i.e. using it as a stand-alone treatment The reviewers [read the full story…]
Aripiprazole (brand names Abilify and Aripiprex) is an atypical antipsychotic drug used to treat a number of mental health disorders including schizophrenia, depression and bipolar disorder. This new guidance has been written by a group of Pan-European experts who have come together to review new clinical guidelines for the management of mania and the role of aripiprazole [read the full story…]
